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Abstract 
Aims 
To determine if sequential application of povidone iodine-alcohol (PVI) followed by 
chlorhexidine gluconate-alcohol (CHG) would reduce surgical wound contamination 
to a greater extent than PVI applied twice in spinal surgery patients. 
Patients and Methods 
A single-centre, interventional, two arm, parallel group randomised controlled trial of 
407 patients attending hospital for elective spinal surgery was conducted. 
For 203 patients, pre-surgical skin disinfection was by application of PVI (10% [w/w 
(1% w/w available iodine)] povidone iodine in 95% industrial denatured alcohol; 
Videne Alcoholic Tincture) twice and for 204 patients application of PVI once 
followed by application of CHG  (2% [w/v] chlorhexadine gluconate in 70% [v/v] 
isopropyl alcohol; Chloraprep with tint). The primary outcome measure was post-skin 
disinfection surgical site contamination determined by aerobic and anaerobic 
bacterial growth from post-skin disinfection samples. 
Results  
The detection of viable bacteria in any one of the post-skin disinfection samples 
(culture-positive) was significantly lower in the group treated with both PVI and CHG 
than in the group treated with PVI alone: 29.1% (59) vs 41.7% (85), P=0.009; relative 
risk, 0.574; 95% confidence interval, 0.380 to 0.866.   
Conclusions 
Skin antisepsis with sequential application of PVI and CHG more effectively reduces 
surgical wound contamination than PVI alone. 
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Take home message: 
1. Sequential skin disinfection with povidone iodine-alcohol followed by chlorhexidine 
gluconate alcohol is more effective at reducing bacterial surgical wound 
contamination than disinfection with povidone iodine alcohol twice. 
2. Bacteria that contaminate surgical wounds derive from the patients’ skin 
microbiota. 
3. Men are more likely to have bacterial surgical wound contamination than women. 
Plain Language Summary: 
The increased risk of infection after surgery due to bacteria becoming resistant to antibiotics 
is a global concern. The source of these infections is often bacteria that are present on the 
patient’s normal healthy skin.  We have shown that by using two different antiseptics to 
disinfect patient’s skin (one after the other), fewer patients have bacteria in the site of 
surgery than if only one type of disinfectant is used. This simple change to antisepsis should 
help to reduce the risk of post-surgical infection, particularly in orthopaedic operations such 
as spinal surgery and insertion of artificial joints. 
 
 
Introduction 
The risk of surgical-site infection is considered to be proportional to the dose and 
virulence of the infective agent in the surgical wound. Implants, including prosthetic  
joints, heart valves, intramedullary nails and metal work used for spinal stabilisation 
can, however, increase the likelihood of infection with bacteria of low primary 
virulence which are capable of causing chronic biofilm-associated infection.1,2  The 
control of surgical site infection at clean operative sites is dependent on the 
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combined efficacy of skin disinfection and peri-operative antibiotic prophylaxis.3,4 
National Institute for Health and Care Excellence UK guidelines state that the most 
effective skin antiseptic before surgical incision ‘remains uncertain’, with either 
aqueous or alcohol-based povidone iodine (PVI) or chlorhexidine being suitable.5 
The spread of antibiotic resistance genes amongst bacteria raises the potential for 
resistance to prophylactic antibiotics leading to higher rates of post-operative 
infection. In addition, bacteria present in the surgical wound can colonise implanted 
biomaterials resulting in chronic infection that may not present until months or years 
after the initial surgery.  The incidence of these biofilm-related infections is likely 
underestimated due to a lack of sampling from the implanted biomaterials and a lack 
of recognition of the importance of Propionibacterium acnes as a pathogen in this 
setting.1,2,6  
PVI and chlorhexidine gluconate (CHG)-based antiseptics are recognised as 
safe to use and have been recommended globally for disinfection of health care 
worker skin and in the pre-operative disinfection of patient skin e.g.4. The disinfectant 
efficacy of alcoholic and aqueous preparations of each, individually, has been 
compared in multiple studies.  For example, in relation to prevention of overt surgical 
site infection, Darouiche and colleagues7 reported that 9·5% of patients disinfected 
with CHG vs 16·1% of patients disinfected with aqueous PVI developed surgical site 
infection.  Comparison of PVI-alcohol versus CHG-alcohol skin disinfection in 
relation to catheter-related infections indicated that CHG treatment resulted in a 
lower incidence of infection.8 The use of PVI and CHG in combination has not, 
however, been examined extensively.  
Both chemicals are microbicidal, but via different mechanisms; the 
antimicrobial activity of CHG is related to its interaction with membranes, whereas 
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microbes are killed by the iodine molecules released from PVI which results in non-
specific nucleophilic attack of microbial components.9,10  
Combined use of aqueous preparations of PVI and CHG in an ex-vivo porcine 
infection model indicated that the two disinfectants are compatible.11 There are a 
small number of studies examining the effect of the sequential use of PVI and CHG 
on skin disinfection that suggest that combined use is more effective. For example, a 
skin swab study of neurosurgery patients12 and the colonisation of central venous 
catheters with the sequential use of CHG and aqueous PVI.13 Neither of these 
studies, and indeed few studies of skin disinfection, investigated anaerobic culture.  
Culture under anaerobic conditions is essential for the optimal isolation of P. acnes 
which is a predominant member of the human skin microbiota and an emerging 
pathogen in relation to biofilm-associated infection.1,14  
The combined use of two antiseptics, each with different microbicidal action, 
may therefore enhance the overall efficacy of the antisepsis. In addition, if there is 
resistance to one antiseptic the second antiseptic may still be effective. 
We hypothesised that the sequential application of 10% [w/w (1% w/w 
available iodine)] povidone iodine (PVI)  in 95% industrial denatured alcohol followed 
by 2% [w/v] chlorhexidine gluconate (CHG)  in 70% [v/v] isopropyl alcohol would be 
more effective at preventing contamination of patient surgical wounds than two 
applications of PVI. We monitored the efficacy of skin disinfection objectively by total 
viable bacterial count of intra-operative surgical site samples of skin, muscle and 
wound wash, not by subjective assessment of overt surgical site infection. To 
determine if the contaminating bacteria were derived from the patient’s skin, bacteria 
isolated from the surgical wound were identified by molecular analyses and 
compared with those isolated from the patient’s skin prior to disinfection. 
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This report is of the first randomised controlled trial to compare the level of 
surgical site wound contamination by bacteria after sequential skin disinfection by 
PVI and CHG with both aerobic and anaerobic bacterial culture and subsequent 
molecular identification of bacterial isolates. 
 
 
 
Patients and Methods 
The Trial was a single-centre, interventional, randomised controlled trial conducted 
at Queen’s University Belfast and the Belfast Health and Social Care Trust, Northern 
Ireland (BHSTCNI), UK. Patients attending for elective spinal surgery were recruited 
at two hospitals within BHSCTNI; Musgrave Park Hospital and the Royal Victoria 
Hospital. The study is a Medicines and Healthcare Products Regulatory Agency 
(MHRA) UK approved Clinical Trial of an Investigational Medicinal Product 
(Reference CTA 32485/0015/001-0001). Ethical approval was obtained from the 
Office for Research Ethics Committees Northern Ireland, Health and Social Care 
Research Ethics Committee 3 (Reference number 09/NIR03/79). Queen’s University 
Belfast and the BHSCTNI were co-sponsors of the Trial. The study is registered with 
the European Clinical Trials database (EudraCT 2009-016566-82) and the 
International Standard Randomised Controlled Trials Register (ISRCTN73863246). 
Patients who were to undergo elective spinal surgery with the two study 
surgeons were invited to participate. Patients were excluded who: were < 18 years 
old; had more than 7 days hospitalisation prior to surgery; had been inpatients in 
another hospital and transferred for surgery; were pregnant; had known sensitivity to 
the skin antiseptics; or had taken antibiotics immediately prior to surgery, other than 
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surgical prophylaxis. In addition, patients with overt spinal infections suspected pre-
operatively or where evidence of purulence in any part of the wound was observed 
during surgery were excluded. Recruitment began 10/05/2010 at Musgrave Park 
Hospital and at the Royal Victoria Hospital 26/08/2011. Consecutive patients were 
enrolled from 23/05/2010 until 07/07/2014.  Written informed consent was obtained 
for all patients recruited to the study. Prior to trial commencement, the randomisation 
schedule was generated by a statistician not involved in the trial or assessing 
outcomes, as detailed in the Supplementary Material. The trial was necessarily open 
label to the patient and hospital staff as the antiseptics have different colours and 
formulation. The Principal Investigator and University staff who analysed and 
recorded bacterial culture from samples were, however, masked to the treatment 
group. 
In the control group, 10% [w/w (1% w/w available iodine)] PVI in 95% 
industrial denatured alcohol (Videne Alcoholic Tincture, Ecolab Ltd, Leeds, UK) was 
applied twice. In the intervention group, PVI was applied once followed by 
application of 2% [w/v] CHG in 70% [v/v] isopropyl alcohol (Chloraprep with tint, 
Enturia Ltd, Reigate, Surrey, UK). Each individual disinfectant application was timed 
and lasted for a minimum of 5 minutes. The primary outcome was surgical wound 
contamination as determined by aerobic and anaerobic viable bacterial counts. The 
main secondary outcome was to determine if there was a relationship between the 
bacteria contaminating the surgical wounds and bacteria associated with the 
patient’s skin. 
Skin surface colonisation prior to disinfection was evaluated by wet-swabbing 
and post-disinfection wound contamination by removal of a skin sample, an erector 
spinal muscle biopsy of longissimus muscle sample and a surgical wound wash 
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obtained by pouring 10 ml of sterile normal saline into the wound with aspiration after 
1 minute as detailed in the Supplementary Material. Samples were transported from 
the operating theatre to the laboratory in an anaerobic pouch and processed under 
anaerobic conditions as detailed in the Supplementary Material. Total viable counts 
(TVCs) were estimated after at least 7 days incubation aerobically and anaerobically. 
Skin and muscle samples were recorded as positive for growth if more than one 
bacterial colony was observed on two or more of the three replicate agar plates. The 
wound wash was recorded as positive if five or more colonies were observed on 
either the aerobic or anaerobic plate. Where there was confluence and single 
colonies uncountable, a minimum count of 1000 was recorded. A surgical site was 
defined as contaminated (culture-positive) if growth was recorded in any one of skin, 
muscle or wound wash samples. 
Operative procedure, age, sex, antibiotic prophylaxis, surgical site shaving, 
timing of antiseptic applications and antibiotic administration were noted. At all times 
theatre staff were working in accordance with normal safety procedures relevant to 
the surgery. Postoperative care was provided according to the principles and 
standards of the participating units.  
The colonisation of each Surgeon’s forehead was evaluated at the trial start, 
middle and end by surface skin swab as detailed in the Supplementary Material.  
For patients with contaminated surgical sites, for each sample (i.e. skin swab, 
skin sample, muscle and wound wash) up to 12 colony forming units (CFUs) were 
archived for molecular identification by PCR amplification and sequencing 
(Supplementary Material, Table S1). For rapid identification of P. acnes, a single 
reaction multiplex touchdown PCR assay was used.15 Bacteria cultured from 
corresponding skin swabs were also analysed. A minimum of four and up to 53 
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isolates were identified to species level per patient; in total 3938 bacterial isolates 
were identified from 141 culture-positive patients. Staphylococcus sp were also 
analysed for the methicillin resistance gene, mecA. 
Statistical analyses  Based on the rate of surgical wound contamination of 
approximately 30%, as indicated by a previous spinal operation study in which PVI 
was used as the pre-surgery skin disinfectant 16, we hypothesised that disinfection 
with PVI followed by CHG would reduce this by 40% compared to the skin 
disinfection with PVI used twice. On this basis it was determined that 197 patients in 
each group would have 80% power to determine a statistically significant difference.  
This assumes a 5% significance level and a two-sided hypothesis. At the request of 
the main funder an Independent Data Monitoring Committee (DMC) carried out a 
confidential interim analysis to determine if the study should cease short of the 
projected target patient recruitment level or if funding should be continued. Data up 
to April 2013 were analysed by the DMC on 22nd May 2013. The DMC recommended 
continuation of the trial to its target sample size. 
Analysis of the primary outcome of the presence of viable bacteria in samples 
post-skin disinfection was by 2-sided Fisher’s Exact Test, with calculation of risk 
estimates and 95% confidence interval.  TVCs were compared by 2-tailed t-test for 
equality of means. Analyses were carried out with IBM SPSS Statistics 22. 
 
Results 
Consecutive adult patients who were to undergo elective spinal surgery were 
enrolled from 23/05/2010 until 07/7/2014; 204 were randomly assigned to skin 
disinfection with PVI used twice and 204 randomly assigned to PVI followed by 2% 
CHG (Figure 1).  One patient was not included in the analysis due to laboratory 
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equipment failure. The baseline patient and surgical characteristics are detailed in 
Table 1, the types of surgery in Table S2 and the antibiotics administered in Table 
S3.  There was one Severe Adverse Event noted: the patient had a nerve injury 
which is a recognised risk of all lumbar spine surgery and was not related to the 
study protocol. There were no adverse skin reactions to either treatments observed. 
The number of patients with viable bacteria detected either aerobically or  
anaerobically in any one of the post-skin disinfection samples (culture-positive) was 
significantly lower in the group treated with both PVI and CHG than in the group 
treated with PVI alone: 29·1% (59) vs 41·7% (85), P=0·009; relative risk, 0·574; 95% 
confidence interval, 0·380 to 0·866 (Table 2). Therefore 30% fewer patients had 
contaminated surgical sites with sequential PVI and CHG disinfection compared to 
patients disinfected with only PVI.  As the number of bacteria internal to the surgical 
site will be relevant in the context of post-operative infection, particularly in relation to 
implant associated biofilm infection, internal surgical site samples of muscle and the 
wound wash were analysed separately from the skin sample data. The number of 
patients with internal surgical site contamination was significantly lower in the PVI 
and CHG group than in the group treated with PVI alone (Table 2). Sequential 
treatment with PVI and CHG therefore resulted in 37·1% fewer patients with bacteria 
internal to their surgical wounds than treatment with PVI alone. Aerobic and 
anaerobic growth were also compared individually and a significant reduction with 
the use of both PVI and CHG treatment was obtained (Table 2). For both treatments 
there were more patients culture-positive for anaerobic growth compared to aerobic 
growth; 138 vs 65.  
There was no significant difference between the treatment groups in relation 
to the surgeon, average age, sex, whether or not the surgical site was shaved, use 
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of ioban drape, incision length, length of time of antiseptic application, the length of 
time between prophylactic antibiotic administration and incision or the type of 
antibiotic administered.  
To determine if either treatment was more efficient at reducing the overall 
bacterial load contaminating the surgical sites, samples with higher TVCs, defined as 
wound wash >=10 CFU ml-1; skin sample >=1000 CFU g-1 and muscle sample>= 
CFU 100 g-1 were analysed.  There was a statistically significant reduction in the 
number of culture-positive patients after the sequential PVI and CHG treatment, with 
the exception of samples with a higher anaerobic growth which was borderline non-
significant (Table 2).  Analysis of the mean TVCs from the culture-positive samples 
with either aerobic or anaerobic growth revealed no statistically significant difference 
between the two treatment groups with respect to the mean TVC (Table S4).  There 
were 45 patients (26 PVI group and 19 PVI/CHG group) with 100 or more CFUs 
present in the wound wash and 24 (14 PVI group and 10 PVI/CHG group) with 1000 
or more CFUs. Irrespective of treatment group, more patients had internal (wound 
wash and muscle sample) growth anaerobically than aerobically (Figure 2).  
None of the patients developed acute surgical site infections. Retrospective 
scrutiny of the patient’s notes indicated that 10 patients had developed superficial 
wound infections post-operatively (PVI alone =7; PVI and CHG=3). Antibiotics had 
been prescribed in eight of these 10 cases. Only four of these patients (two from 
each study treatment) had culture-positive post-skin disinfection surgical samples 
(Table 3). The lack of serious post-surgical infection likely reflects the current 
efficacy of the prophylactic antibiotics. 
Representative individual bacterial CFUs, in total 3938 from 141 culture- 
positive patient samples, were identified to species level. The patients’ isolates 
13 
 
 
belonged to the Staphylococcaceae, Propionibacteriaceae and Micrococcaceae 
(Table 4), with the exception of a small number of individuals from whom other 
species were isolated from either the skin swab or skin samples (Table S5).  
S. aureus was isolated from a single patient skin swab. MecA+ 
Staphylococcus species were detected in 37 of the culture-positive patients. The 
isolation of facultative CoNS, obligately anaerobic S. saccharolyticus, 
Micrococcaceae and P. acnes aerobically and anaerobically from individual patient 
samples were compared (Figure 3). There was no statistically significant difference 
between the two treatments in relation to distribution of the types of bacteria isolated.   
Comparison was made with bacteria identified from the skin (the pre-skin 
disinfection skin swab or post-skin disinfection skin sample) and the internal surgical 
wound samples of muscle and wound wash for each patient where culture data were 
available. The same species, or in the case of P. acnes the specific phylogroup, 
were identified on or in the skin and internal to the surgical wound in 96 of the 101 
patients with bacteria internal to the surgical wound. This indicates that the bacteria 
from the patient’s skin are contaminating the surgical site.   
There was no significant difference between the mean estimated total viable 
numbers of skin surface bacteria prior to skin disinfection and the treatment group;   
however, men (n= 195) had significantly higher mean skin surface TVCs than 
women (Figure 4).   Ninety-seven patients underwent a pre-surgery shave in theatre 
(90 men and 7 women) (Table 5) prior to application of the first antiseptic (Average 4 
min before, maximum 19 min before).  Fifty were in the PVI treated group and 47 in 
the PVI and CHG group.  
Patients whose surgical site samples were culture-positive, irrespective of 
treatment, had significantly higher skin surface TVCs pre-skin disinfection (Table 6 
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and Figure 5).  Culture-negative patients had a mean skin surface TVC of less than 
102 cm-2.  Culture-positive patients had mean skin surface aerobic TVC of greater 
than 102 cm-2 and greater than 103 cm-1 for anaerobic growth. This indicates that 
patients with a higher total viable surface skin count are more likely to have viable 
bacteria present within the surgical wound. There was no significant difference 
between the treatment groups and sex 53·3% (104) males in the PVI group vs   
46·7% (91) in the PVI and CHG group, P=0·234); however, there was a significant 
difference in the sex distribution and culture-positive patients with more culture- 
positive men than women in both treatment groups (Figure 6).  This was reflected by 
a significant difference in the skin swab TVCs between men and women (Figure 4).   
The foreheads of the two surgeons who carried out the surgical operations 
were each swabbed on 3 separate occasions. TVCs were carried out, the 
predominant bacteria identified and Staphylococcus spp screened for the mecA 
gene (Table 7A and B). Neither of the surgeons were colonised by mecA + 
Staphylococcus spp; however, mecA + Staphylococcus were identified in samples 
from two patients who had operations on days the surgeons were sampled.  
 
Discussion 
There have been numerous studies of the efficacy of pre-surgery skin antisepsis in 
relation to subsequent surgical site infection in which different preparations of CHG 
and PVI were compared; however, these have been limited by the numbers of 
patients studied and the low incidence of surgical site infections.17 The current study 
was not designed to investigate surgical site infection, but to determine levels of 
viable bacteria at the surgical site after skin disinfection.  The advantage of this 
approach is that there was no subjective assessment of infection and although the 
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application of the antiseptics in the theatre could not be masked, the laboratory staff 
carrying out the bacterial culture and recording the viable bacterial counting were 
masked to treatment group. Also, antiseptic efficacy based on surgical site infection 
would have required a much larger number of participants due to the low incidence 
of surgical site infection. The data show that the use of PVI followed by CHG 
reduces internal surgical wound contamination, defined as bacterial culture from 
either the surgical site muscle sample or wound wash, by 37·1% compared with the 
use of PVI alone.  Therefore sequential use of PVI and CHG results in fewer patients 
with bacteria contaminating their surgical wounds. This significant reduction is 
important in the context of the potential increase of bacterial antimicrobial resistance 
to antibiotics used to provide surgical prophylaxis.  In addition, the use of both 
antiseptics could potentially reduce biofilm infection of implanted medical devices, 
where bacteria contaminating the surgical site colonise the implanted material.  A 
limitation of our study is that the application of CHG twice was not investigated. 
Comparison with other published studies comparing the skin disinfection efficacy of 
PVI and CHG application is difficult due to methodological differences and 
differences in the criteria used to assess the potential for wound contamination.  For 
example, Saltzman and colleagues18 investigated culture from only dry swabs pre- 
and post- disinfection in relation to shoulder surgery and compared treatment with 
aqueous PVI scrub and paint, an alcoholic iodophor preparation and alcoholic CHG.  
The methodology used by these authors subsequently to culture from the swabs is 
unclear although cultures were incubated both aerobically and anaerobically. These 
authors, however, do report a significant reduction in the isolation of CoNS with the 
use of the alcoholic preparations but no significant reduction in the isolation of P. 
acnes. Langgartner and colleagues13 compared CHG (0·5%) alcohol, aqueous PVI 
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(10%) and their use in combination in relation to inserted central venous catheter 
insertion. Bacteria were cultured from 24·4% of the CHG alcohol treated, 30·8% of 
the PVI treated group and 4·7% of the CHG-propanol followed by PVI treatment 
group, indicating increased effectiveness of the combined treatment; however, the 
PVI was an aqueous preparation and anaerobic culture was not investigated.  
Although we did not investigate whether or not the sequential use of alcoholic CHG 
and alcoholic PVI is also more effective than alcoholic CHG used twice, our data 
clearly indicates an advantage over the use of alcoholic PVI alone.  It should be 
noted that an added advantage of the use of two different antiseptics sequentially is 
the potential protection against current and future antiseptic resistance. 
Substantial surgical site contamination with viable bacteria post-skin 
disinfection also has important implications for the diagnosis of infection reliant on 
culture from intra-operative tissue samples and for implant-associated infection in 
particular. The guidelines for the intraoperative diagnosis of prosthetic joint infection 
by culture recommend analysis of up to six separate tissue samples, with growth of 
the same organism from two or more samples being considered as definitive 
evidence of infection.19 Our data showed that 101 patients (62 PVI group, 39 PVI and 
CHG group) had viable bacteria within the surgical wound in numbers ranging from 
10 to over 1000 CFU. The surgical wounds were only on average 7.7cm in length; it 
is possible that larger surgical wounds, such as those for revision arthroplasty, could 
result in even greater surgical wound contamination. The diluent wash of retrieved 
implants to remove surgical site contaminating bacteria and subsequent mild ultra-
sound treatment to dislodge bacterial biofilm followed by microscopical and culture 
examination20 may be a more reliable diagnostic for prosthetic joint infection.   Our 
data are also important in relation to determining if there is a link between lumbar 
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disc degeneration and chronic infection by P. acnes21 as clearly tissue removed from 
the surgical site can readily be contaminated by the patient’s skin microbiota entering 
the surgical wound. Distinguishing between contamination and infection therefore 
has to be addressed in any studies to investigate this association. 
Both treatments were less effective at reducing the contamination of the 
surgical site by anaerobic bacteria, which may relate to the higher numbers of 
anaerobic bacteria compared with aerobic bacteria pre-skin disinfection. P. acnes 
was the predominant species identified from anaerobic culture. P. acnes is a 
recognised cause of implant associated biofilm-infections1,22  and is capable of 
causing biofilm infection and pyogenic osteomyelitis in the absence of wear debris 
from the implanted material.23   The obligately anaerobic coagulase negative 
Staphylococcus saccharolyticus was also identified from anaerobic culture. There 
are few reports of S. saccharolyticus as a cause of infection, which may relate to lack 
of investigation of anaerobic coagulase negative staphylococci (CoNS).  It has, 
however, been reported as a cause of spondylodiscitis.24 
This is the first study in which multiple isolates (3938 isolates from 141 
patients) of numerically dominant bacteria from the surgical sites of individual 
patients have been identified using molecular methods. Our data clearly indicate that 
patient’s skin is the source of the contaminating bacteria and not the operating 
surgeons. By molecular identification, bacterial species and types cultured from the 
patient’s skin and from within the surgical site could be matched in 95% (95/101) of 
culture-positive patients. Bacteria cultured from the foreheads of the surgeons did 
not match bacteria from the surgical sites of patients from the corresponding dates. 
MecA+  CoNS were isolated from 25% of culture-positive patients, but not from the 
surgeons. The clear relationship between higher pre-skin disinfection TVC and 
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surgical site contamination provides further evidence for the patient’s skin as the 
source of wound contamination. The data also revealed a clear sex difference; men 
had higher pre-skin disinfection TVC than women and were twice as likely to have 
surgical wound contamination.  Men were also more likely to be shaved; only 7 of the 
97 patients who were shaved were female.  A number of publications indicate that 
men are more likely than women to have infections following medical implant related 
surgery (reviewed in 25). Whether or not this relates to men having a higher bacterial 
load in and on their skin remains to be determined. 
In conclusion, the pre-operative sequential use of PVI and CHG is likely to 
reduce the risk of post-operative biofilm associated infections arising where 
operations involve implanted biomaterials, in particular in relation to facultatively 
anaerobic coagulase negative Staphylococcus spp; however, further improvement to 
skin disinfection protocols needs to be investigated for patients with high P. acnes 
skin total viable counts, given its role in implant infection.  Even with the improved 
skin disinfection of PVI and CHG, 39 (19.2%) patients had viable bacteria within the 
surgical site. Therefore the diagnosis of implant-associated infection based on 
culture from intra-operative tissue sampling also needs to be re-addressed. 
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Table 1. Baseline patient and surgery characteristics 
 
PVI + PVI 
Group (n=204) 
PVI + CHG Group 
(n=203) 
Sex   
Female 100 (49%) 112 (55%) 
Male 104(51%) 91 (45%) 
Age (years)  44 (36-52) 47 (38-58) 
Surgery details   
Surgeon 1 121 (59%) 124 (61%) 
Surgeon 2 83(41%) 79 (39%) 
Surgical site shaved 50 (25%) 47(23%) 
Systemic antibiotics 203 203 
Incision length (cm) 7·7 (+5·1) 7·7 (+4·0) 
Ioban drape 30 (14·7%) 31 (15·3%) 
Implanted metal work 36 (17·6%) 40 (19·7%) 
Surgical site   
Anterior cervical 12 (5·9%) 13 (6·4%) 
Anterior thoracic 1 (0·5%) 0 
Posterior cervical 5 (2·5%) 6 (3·0%) 
Posterior cervico-thoracic junction 1 (0·5%) 0 
Posterior lumbar 179 (87·7%) 180 (88·7%) 
Posterior thoracic 3 (1·5%) 2 (1·0%) 
Posterior thoraco-lumbar junction 3 (1·5%) 2 (1·0%) 
Data are n (%), 1median (IQR), 2 mean (SD). PVI = povidone-iodine alcohol. 
CHG =chlorhexidine gluconate alcohol. 
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Table 2. Proportion of patients with bacterial contamination of surgical site samples after skin disinfection 
 
Positive 
patients  
Total 
(n=407) 
Positive 
patients in 
PVI + PVI 
Group 
(n=204) 
 
Positive 
patients in 
PVI + CHG 
Group 
(n=203) 
1P 
value 
Odds 
ratio 
2CI  
Lower 
CI 
Upper 
Difference in 
positive 
patients 
between 
groups 
3Culture-positive  144 (35·4%) 85 (41·7%) 59 (29·1%) 0·009 0·574 0·380 0·866 26 (30·6%) 
4 Internal samples culture-positive 101 (24·8%) 62 (30·4%) 39 (19·2%) 0·011 0·545 0·344 0·862 23 (37·1%) 
Aerobic culture-positive 65 (16·0%) 45 (22·1%) 20 (9·9%) 0·001 0·386 0·219 0·681 25 (55·6%) 
Anaerobic  culture-positive 138 (33·9%) 79 (38·7%) 59 (29·1%) 0·047 0·648 0·429 0·980 20 (25·3%) 
5High Total Viable Count 114 (28·0%) 67 (32·8%) 47 (23·2%) 0·036 0·616 0·398 0·955 20 (29·8%) 
High Aerobic Total Viable Count   33 (8·1%) 23 (11·3%) 10 (4·9%) 0·028 0·408 0·189 0·880 13 (56·5%) 
High Anaerobic Total Viable Count 112 (27·5%) 65 (31·9%) 47 (23·2%) 0·059 0·644 0·415 1·000 18 (27·7%) 
1P value, Fisher's Exact Test (2-sided) 
295% Confidence Interval 
3Skin sample/Muscle Sample/Wound Wash 
4 Muscle sample/Wound wash 
5Skin sample >=1000 g-1, Muscle sample >=100 g-1, Wound Wash >=10 ml-1 
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Table 3. Patients with post-operative wound infection 
Surgical 
disinfection  
Treatment 
Surgical 
site 
samples 
Culture- 
positive 
Infection Notes Antibiotics 
prescribed 
PVI + PVI N developed wound infection, settled with antibiotics Y 
PVI + PVI N small ooze from wound Y 
PVI + PVI N 
wound came apart, required re-admission and washout, 
patient recovered Y 
PVI + PVI Y superficial wound infection settled Y 
PVI + PVI Y oozing wound, settled Y 
PVI + PVI N delayed wound healing with ooze Y 
PVI + PVI N ulcerated wound N 
PVI + CHG Y wound ooze N 
PVI + CHG N superficial wound infection, recovered Y 
PVI + CHG Y superficial wound infection, settled Y 
Y = yes, N = no 
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Table 4. Comparison of the bacterial species cultured from the skin and within the 
surgical wound 
 Bacterial Species Identified 
Taxonomic Family   
 Skin (swab1 or sample2) Wound2 (muscle sample or 
wash) 
Staphylococcaceae S. aureus  
Staphylococcaceae  
(Coagulase-negative) 
S. capitis, S. capitis subsp 
capitis, S. capitis subsp 
urealyticus, S. caprae, S. 
epidermidis, S. saccharolyticus 
S. capitis, S. capitis subsp capitis, S. 
capitis subsp urea, S. caprae, S. 
epidermidis, S. saccharolyticus 
 S. cohnii, S. cohnii subsp 
urealyticus, S. equorum, S. 
saprophyticus 
S. saprophyticus 
 S. haemolyticus, S. hominis, S. 
hominis ss hominis, S. hominis 
ss novobiosepticus, S. jettensis 
 S. hominis  
 S. lugdunensis S. lugdunensis 
 S. lentus  
 S. simulans S. simulans 
 S. pasteuri, S. warneri S. pasteuri, S. warneri 
 Staphylococcus sp. Staphylococcus sp. 
Propionibacteriaceae Propionibacterium acnes  
Type IA1, IA2, IB, IC, II, III 
Propionibacterium acnes  
Type IA1, IA2, IB, IC, II, III 
 P. avidum  
 P. granulosum P. granulosum 
 Propionibacterium sp Propionibacterium sp 
Micrococcaceae Micrococcus luteus, 
Micrococcus yunnanensis, 
Kocuria rhizophila, Kocuria sp 
Micrococcus luteus, Micrococcus 
yunnanensis  
1 pre-skin disinfection, 2 post-skin disinfection. 
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Table 5. Comparison of pre-skin disinfection TVCs for aerobic and anaerobic growth for the different treatment 
groups and patients who were shaved 
 
Skin Swab Group 
N 
TVC 
(Log10 CFUs cm
-1) 
Mean 
Std. 
Deviation 
Std. Error 
Mean 
2-tailed t-test for 
Equality of 
Means 
P (0.05) 
Aerobic PVI + PVI  203 1·66 1·42 0·10 
0·466 
PVI + CHG  203 1·56 1·28 0·09 
Anaerobic PVI + PVI  204 2·40 1·65 0·12 
0·336 
PVI + CHG  203 2·25 1·42 0·10 
Aerobic Not shaved 310 1·55 1·31 0·07 
0·083 
Shaved 96 1·82 1·48 0·15 
Anaerobic Not shaved 310 2·21 1·49 0·08 
0·006 
Shaved 97 2·70 1·62 0·16 
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Table 6. Comparison of skin swab TVCs for culture-positive and -negative patient from the two treatments 
groups 
Treatment 
Group 
Skin Swab 
1Culture 
 
N TVC  
(Log10 CFUs cm
-2) 
Mean 
Std. 
Deviation 
Std. Error 
Mean 
2-tailed t-test for 
Equality of Means 
P (0.05) 
PVI + PVI  Aerobic 2- 119 1·19 1·14 0·10 
<0·001 
+ 84 2·33 1·52 0·17 
Anaerobic - 119 1·60 1·29 0·12 
 <0·001 
+ 85 3·52 1·44 0·16 
PVI + CHG  Aerobic - 144 1·32 1·12 0·09 
<0·001 
+ 59 2·16 1·45 0·19 
Anaerobic - 144 1·75 1·17 0·10 
<0·001 
+ 59 3·49 1·18 0·15 
  3Internal 
culture 
     
PVI + PVI  Aerobic - 142 1·32 1·24 0·10 
<0·001 
+ 61 2·44 1·53 0·20 
Anaerobic - 142 1·87 1·44 0·12 
<0·001 
+ 62 3·62 1·43 0·18 
PVI + CHG  Aerobic - 164 1·41 1·19 0·09 
<0·001 
+ 39 2·21 1·47 0·24 
Anaerobic - 164 1·97 1·29 0·10 
<0·001 
+ 39 3.46 1.30 0.21 
1  Any post-skin disinfection sample 
2  -, negative; +, positive 
3  Muscle and/or Wound wash sample 
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Table 7A. Comparison of bacteria identified from surgeon skin swab and patient undergoing surgery 
 Surgeon 
 
Patient 
Date Surgeon 
number 
(no. of cfu 
identified) 
Skin Swab Patient 
number 
Skin Swab Skin Sample Muscle/
Wound 
wash 
12/05/2010 1 
(26 cfu) 
Staphylococcus 
epidermidis; 
Kocuria sp 
Propionibacterium 
acnes type IA1; IB 
2  
3 
4 
ND 
ND 
Acinetobacter lwoffii;  
S. caprae;  
S. epidermidis; 
P.  acnes type IB; III 
Negative 
Negative 
P. acnes type II 
Negative 
Negative 
P. acnes 
type II 
20/02/2012 1 
(26 cfu) 
S. epidermidis;  
P. acnes type IA1; 
IB;II 
177 
 
178 
ND 
 
ND 
 
 
S. caprae;  
S. haemolyticus; 
Ralstonia 
insidiosa 
Negative 
 
Negative 
16/06/2014 1 
(26 cfu) 
S. caprae;  
S. epidermidis;  
S haemolyticus;  
S. warneri;  
P. acnes type IA1;IB; 
II 
421 
 
 
 
 
423 
 
Kocuria rhizophila; 
S. epidermidis 
mecA+; 
S. hominis mecA+; 
P. acnes IA1; IC 
 
Moraxella osloensis; 
S. epidermidis; 
S. haemolyticus: 
S. hominis: 
P. acnes type IA1; II; 
III 
 
Negative 
 
 
 
 
 
Negative 
Negative 
 
 
 
 
 
Negative 
10/05/2010 2 
(20 cfu) 
Microbacterium 
aurum;  
P. acnes type IA1; IB 
1 Micrococcus 
yunnanensis; 
S. epidermidis 
S. lugdunensis 
Negative Negative 
23/07/2012 2 
(14 cfu) 
P. acnes type IB 216 
217 
218 
ND Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
23/06/2014 2 
(20 cfu) 
Kocuria rhizophila; 
Micrococcus sp; 
Roseomonas 
mucosa;  
S. capitis;  
S. caprae; 
Staphylococcus sp;  
P. acnes type IB; II 
424 S. epidermidis 
mecA + 
S. lugdunensis 
mecA+ 
P. acnes type IA1 
P. acnes type IA1 Negative 
ND, not done 
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Table 7B. Surgeon skin swab TVCs  
Date Surgeon Aerobic  
CFUs cm-2 
Anaerobic 
CFUs cm-2 
12/05/2010 1 4.00E+03 1.13E+03 
20/02/2012 1 3.50E+02 5.90E+04 
16/06/2014 1 3.30E+02 2.20E+03 
10/05/2010 2 7.20E+04 9.90E+03 
23/07/2012 2 9.00E+01 6.40E+04 
23/06/2014 2 2.50E+02 3.20E+03 
557 Patients approached 
30 Refused to participate 
12 Excluded 
1 Sensitivity to skin antiseptic 
3 Antibiotic treatment 
2 Patient already participated 
3 Patient in hospital for >7 days  
    prior to surgery 
1 Infection  
2 Not attending for spinal surgery 
4   Patient did not attend 
28 Laboratory unable to process samples 
75 Surgery cancelled 
64 by surgical staff 
11 by patient 408 Patients enrolled 
204 Randomly assigned to 
10% [w/w (1% w/w available iodine)] 
 povidone iodine in  95% [v/v] industrial 
denatured alcohol used twice 
204 Randomly assigned to 
10% [w/w (1% w/w available iodine)] 
 povidone iodine in 
 95% [v/v] industrial denatured alcohol  
followed by 
2% [w/v] chlorhexadine gluconate in 
70% [v/v] isopropyl alcohol  1 not included in analysis 
 due laboratory  
equipment failure 
203 included in analyses 204 included in analyses 
Figure 1: Trial profile 
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
0 0.5 1 1.5 2 2.5
To
ta
l V
ia
b
le
 C
o
u
n
t 
  
(L
o
g 
1
0 
C
FU
 1
0
m
l-1
  W
o
u
n
d
 w
as
h
/ 
  
g 
-1
M
u
sc
le
 s
am
p
le
) 
A 
1.00
1.50
2.00
2.50
3.00
3.50
4.00
4.50
0 0.5 1 1.5 2 2.5
To
ta
l V
ia
b
le
 C
o
u
n
t 
  
(L
o
g 
1
0 
C
FU
 1
0
m
l-1
  W
o
u
n
d
 w
as
h
/ 
  
g-
1
 M
u
sc
le
 s
am
p
le
) 
B 
PVI + PVI PVI + PVI PVI + CHG PVI + CHG 
WOUND WASH MUSCLE SAMPLE 
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Figure 2: Total viable counts for muscle sample and wound wash for 
anaerobic (A) and aerobic growth (B) for each treatment group. Bar = 
mean. No statistical significance between the means of the two 
treatment groups by 2-tailed t-test for equality of means.  (Appendix 
Table S4). 
PVI= povidone iodine-alcohol. CHG= chlorhexidine gluconate-alcohol. 

Figure 3: Frequency (%) of different types of 
bacteria isolated under aerobic and anaerobic 
conditions from skin swab (A,B), skin sample 
(C,D), muscle sample (E,F) and wound wash 
(G,H), as a proportion of the total isolates 
identified for each sample (A,C,E,G) and for 
each treatment (B,D,F,H). 
CoNS= coagulase negative Staphylococcus 
spp, except for S. saccharolyticus. 
PVI= povidone iodine-alcohol 
CHG= chlorhexidine gluconate alcohol 
*P= 0·018 
*P< 0·001 
Females          Males Males Females 
Aerobic Anaerobic 
A B 
Figure 4: Comparison of skin swab aerobic and anaerobic  total viable counts for males and females.  
Bar=mean. * = Statistically significant by 2-tailed t-test for equality of means P (0·05). 
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Figure 5: Comparison of pre-skin disinfection skin swab aerobic and anaerobic total viable counts (TVCs) for post-skin disinfection  surgical 
sample culture positive and negative patients. Aerobic TVCs (A,C), anaerobic TVCs (B,D). Povidone iodine-alcohol twice treatment (A,B), 
Povidone iodine-alcohol followed by chlorhexidine gluconate treatment (C,D).   Bar=mean. * = Statistically significant by 2-tailed t-test for 
equality of means P (0·05).   
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Figure 6: Comparison of the number of males and females with culture positive post-skin disinfection 
surgical samples. * = statistically significant by Fisher’s exact test (2-sided) P (0·05). 
PVI= povidone iodine-alcohol. CHG= chlorhexidine gluconate-alcohol. 
N
u
m
b
er
 o
f 
p
at
ie
n
ts
 
Supplementary on-line material 
Methods 
Randomisation and masking: Prior to trial commencement, the randomisation 
schedule in 500 sealed individually numbered (1-500) opaque envelopes, was 
generated by a statistician who was not involved in the trial or assessing outcomes. 
Patient recruitment began on 10/05/2010 at Musgrave Park Hospital. Recruitment at 
the Royal Victoria Hospital began on 26/08/2011. A unique anonymous identifier 
number code was assigned for each patient.  Patients were enrolled at the hospital 
sites by a Research Nurse or assistant not involved in determining bacterial culture 
from samples. In advance of the patient’s operation day, the randomisation envelope 
was opened on the hospital site in numerical order and patients were allocated to 
one of the two treatment groups. The Surgeon then completed a trial specific 
prescription form which was presented to the Hospital Pharmacy. On the day of the 
patient’s operation, the clinical trial antiseptics were transported from the hospital 
Pharmacy to the Scrub Nurse in Surgical Theatre. The trial was necessarily open 
label to the patient and hospital staff as the antiseptics have different colours and 
formulation. The Principal Investigator and staff at the University who analysed and 
recorded bacterial culture from samples were, however, masked to the treatment 
group. 
Surgical procedures: Skin surface colonisation prior to disinfection was evaluated 
by wet-swabbing.  The site of surgical incision was marked along with a 5 x 2 cm 
sampling area on the patient’s skin covering where the surgical incision was to be 
made. The tip of a sterile sample swab (TSC Ltd., Lancashire, UK) was soaked in 
sterile swab tip solution (STS; 0.075M phosphate buffer, pH 7.0, containing 0.1% 
[v/v] Triton X-100) for 5 sec before being evenly rubbed with slight pressure over the 
marked sampling area for 1 min to remove any surface bacteria.  
After the swab had been taken the disinfectants were applied. Each individual 
application was timed and lasted for a minimum of 5 minutes. If required, x-rays were 
taken between the two applications. Sterile drapes were then applied and the 
incision was made. The extent of surgical site contamination after skin disinfection 
was evaluated by processing three samples: a) a skin sample of approximately 
2mm³ was taken from the incision site and transferred to a sterile container by the 
Surgeon, b) an erector spinal muscle biopsy of longissimus muscle sample of 
approximately 2mm³ was removed and handled as above and c) a surgical wound 
wash. The latter was obtained by pouring 10 ml of sterile normal saline into the 
wound immediately following removal of the muscle sample. After 1 min the saline 
wound wash was aspirated using a sterile syringe and transferred to a sterile 
container. Operative procedure, age, sex and antibiotic prophylaxis were noted for 
each patient. Shaving of the patient’s surgical site before antiseptic application was 
noted. Times between antiseptic applications and before removal of the skin sample 
collection were recorded. The antibiotics and time of administration was noted. At all 
times theatre staff were working in accordance with normal safety procedures 
relevant to the surgical procedure. Postoperative care was provided according to the 
principles and standards of the participating units. 
The colonisation of each Surgeon’s forehead was evaluated at the trial start, 
middle and end by surface skin swab. Once the Surgeon had completed the surgical 
scrub, gown and glove procedure and moved beside the patient ready to begin the 
operation, a 5 x 2 cm sampling area on the forehead visible below the surgeon’s cap 
was marked out and swabbed in the same manner as for the patient skin. 
 Sample processing: When all the samples were available in the operating theatre, 
the sample containers were placed into an anaerobic pouch with an AnaeroGen 
anaerobic atmosphere gas generation system sachet (AGS, Oxoid Ltd., Hampshire, 
England), excess air expelled and the anaerobic bag firmly sealed. The lids of the 
tissue specimen containers were slightly loosened prior to placing in the anaerobic 
pouch to allow anaerobic gas entry. The anaerobic bag was then placed in a 
disinfected jar and the lid sealed for safe transport to the laboratory. In the 
laboratory, samples were placed in an anaerobic workstation (Don Whitley MACS 
MG1000 Anaerobic Workstation, Don Whitley Scientific Ltd., Shipley, UK)  
interchange and once an anaerobic atmosphere was attained, transferred to the 
workstation (Gas atmosphere: 80% N2, 10% CO2, and 10% H2) for processing. To 
minimise areal contamination within the anaerobic workstation, the gas atmosphere 
was continuously pumped through a solution of glutaraldehyde (2% v/v) and surgical 
gloves worn throughout processing.  The following agar media were used: pre-
poured fastidious anaerobic horse blood agar (BA; Fannin LIP Diagnostic Services, 
Galway, Ireland) and mannitol salt agar (MSA; Fannin LIP Diagnostic Services, 
Galway, Ireland) and in-house prepared tryptone yeast extract agar plates containing 
6 mg/ml furazolidone (Propionibacterium acnes selective agar; PSA). Sterile pre-
reduced Quarter Strength Ringer’s Solution (rQSRS) containing cysteine (0.05% 
[w/v]) as a reducing agent was used as a diluent. Agar plates, diluent and containers 
were pre-incubated for a minimum period of 48 hours within the anaerobic 
workstation prior to use to ensure anaerobic conditions. All agar plates were also 
pre-incubated to ensure sterility and the ability of agar plates to support bacterial 
growth was quality controlled by inoculation of selected plates with P. acnes NCTC 
737 (BA and PSA), Staphylococcus aureus NCTC8530 and S. epidermidis NCTC 
11047 (BA and MSA). 
Total viable counts (TVCs) were estimated for the skin swab by two 10-fold 
dilutions. The swab tip was cut and placed in QSRS (1ml), vortexed and diluted. 
Replicate 20 microlitre drops of undiluted (6 drops) and diluted samples (5 drops 
each) were applied to duplicate BA plates and each set incubated either in the 
anaerobic workstation or aerobically at 37oC.   
TVCs for the skin and muscle samples were estimated as follows: with the lid 
tightened, the sample jar containing the skin sample was removed from the 
anaerobic workstation and weighed. The container was then placed back into the 
workstation and the skin sample removed using sterile forceps and finely cut with 
sterile scissors in a sterile plastic petri dish. Sterile forceps were used to place the 
skin sampling into a sterile plastic 7ml container containing ceramic beads (Precellys 
Hard Tissue Homogenizing Tubes, Stretton Scientific, Derbyshire, UK) and 6 ml 
rQSRS. The cap was securely tightened and the container vortexed for 1 min. With 
the exception of 11 patients (6 PVI treated and 5 PVI +CHG treated) the samples 
were ultrasound treated to dislodge follicular biofilm as follows:  with the lid tightly 
screwed down, the container was removed from the cabinet and placed in an 
ultrasound bath (Decon F5200b, D&H Ltd., Belfast, UK) pre-disinfected  with 70% 
(v/v) IDA and air dried, and to which sterile distilled water had been added. The 
container was sonicated for 5 min @ 50 kHz . The container was transferred back 
into the anaerobic workstation and 0.5 ml of suspension was spread onto each of six 
BA plates, three PSA plates and three MSA plates using sterile plastic disposable 
spreaders. After drying, each set was incubated either in the anaerobic workstation 
(3 x BA and 3 x PSA) or aerobically (3 x BA and 3 x MSA) at 37oC. All plates were 
incubated for 7 days. 
The muscle sample was weighed within the container as for the skin sample 
and inside the anaerobic workstation transferred to a sterile glass universal bottle 
containing 10 ml rQSRS, sonicated and the diluent plated as for the skin sample. 
Sample weights were determined by subtracting the weights of the empty containers. 
The wound wash sample was poured into a sterile, graduated centrifuge tube 
within the anaerobic workstation, firmly closed, the volume recorded and the tube 
centrifuged to pellet the cells. The tube was then returned to the anaerobic cabinet 
and supernatant carefully aspirated to leave a volume of 1ml remaining. The tube 
was vortexed to re-suspend the pelleted cells and 0.5ml was spread onto two BA 
plates. One plate was incubated in the anaerobic workstation and the other 
aerobically, at 37°C.  Wound wash samples were not taken from 22 patients (10 PVI 
treated and 12 PVI +CHG treated) and not processed for a further 21 patients (15 
PVI treated and 6 PVI +CHG treated) due to clotting of the sample. 
TVCs were estimated after culture under aerobic and anaerobic conditions 
after at least 7 days incubation. The number of colony forming units (CFUs) were 
recorded using a colony counter with magnifying glass (Stuart®, Bibby Scientific Ltd., 
Staffordshire, UK) along with colony morphologies. TVCs were expressed as CFUs 
cm-2 for skin swab, CFUs g-1 wet weight for skin and muscle samples and CFUs ml-
1 of wound wash. 
Skin and muscle samples were recorded as positive for growth if more than 
one bacterial colony was observed on two or more of the 3 replicate agar plates. The 
wound wash was recorded as positive if there were five or more colonies observed 
on either the aerobic or anaerobic plate. In instances where there was confluence 
and colonies were uncountable a minimum count of 1000 was recorded. A surgical 
site was defined as contaminated (culture positive) if growth was recorded in any 
one of skin, muscle or wound wash samples. 
For patients with contaminated surgical sites, for each sample type (i.e. skin 
swab, skin sample, muscle and wound wash) up to 12 CFUs, representatives of the 
colony morphotypes were archived in microtitre trays and stored at -80oC for 
subsequent molecular identification. For confluent TVC plates, a loop was swept 
across the agar surface and re-streaked to single colonies from which representative 
morphotypes were then archived.  
Bacterial Identification: Archived cultures were sub-cultured onto BA plates to 
ensure purity and DNA lysates were prepared by suspending a single CFU in 200 µl 
of ultrapure H2O in a sterile 1.5 ml Eppendorf tube. This was vortexed for 30 secs 
and then placed in a microwave oven for a total of 5 mins in 30 sec bursts. The 
lysate was then cooled on ice for 1 min before being centrifuged at 16000 g for 6 
minutes to remove cell debris (Eppendorf 5415D Centrifuge). The supernatants were 
stored at -20oC until PCR amplification analyses.  16S rRNA , glyceraldehyde-3-
phosphate dehydrogenase (gap) and mecA gene PCR fragments (Table S1) were 
amplified by PCR and products were run on a E-gel 48 (2% agarose; Invitrogen) to 
verify the size of the PCR product. The product were then purified and sequenced by 
GATC Biotech AG (Sanger sequencing, SUPREMErun 96 Applied Biosystems 
3730xl DNA Analyser). Raw sequences were manually trimmed and interpreted 
using Chromas Lite (v2.6, http://www.technelysium.com.au/chromas.html) to ensure 
the quality of the sequence. Trimmed sequences were queried using a Standard 
Nulceotide BLAST (Basic Local Alignment Seach Tool, National Centre for 
Biotechnology Information, https://blast.ncbi.nlm.nih.gov/Blast.cgi) and NCBI 
database was used to find the closest sequence match, by using BLASTN algorithm.  
After an initial screen by PCR amplification using universal 16s rRNA gene primers1 
(Table S1) and sequencing, colony morphotypes that were indicative of 
Staphylococcus species were analysed with glyceraldehyde-3-phosphate 
dehydrogenase (gap) gene primers2 (Table S1) for more accurate species 
identification and also for the presence of mecA which encodes meticillin resistance.3  
Colony morphotypes indicative of Propionibacterium species were analysed 
by a single reaction multiplex touchdown PCR assay as described previously20 for 
rapid identification of P. acnes.  Isolates that were negative for P. acnes multiplex 
analyses were re- analysed using the 16s rRNA gene universal primers.  Where 
available, a minimum of 2 and up to 22 representative colony morphotypes from 
individual surgical samples were identified to species level. Bacteria cultured from 
corresponding skin swabs were also analysed. This represents a minimum of 4 and 
up to 53 isolates identified per patient; in total 3938 bacterial isolates from 141 
culture positive patients. 
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Table S1. PCR amplification primer sequences for bacterial identification 
Target Gene Forward Reverse 
Universal Bacterial 
16S rRNA gene1 
5’-AGTTTGATCCTGGCTCAG-3’ 
 
5’-GGTTACCTTGTTACGACTT-3’ 
 
Staphylococcus sp. gap 
2 
5’-ATGGTTTTGGTAGAATTGGTCGTTTA-3’ 
 
5’-GACATTTCGTTATCATACCAAGCTG-3’ 
 
mecA 3 5’-TGGCTATCGTGTCACAATCG-3’ 
 
5’-CTGGAACTTGTTGAGCAGAG-3’ 
 
 Table S2.  Types of surgery 
 
 Total 
PVI + PVI 
Group (n=204) 
PVI + CHG 
Group 
(n=203) 
Anterior Cervical Corpectomy 1 (0·2%) 0 1 (0·5%) 
Anterior Cervical Discectomy and Fusion 22 (5·4%) 11 (5·4%) 11 (5·4%) 
Anterior Cervical Discectomy and Instrumented Fusion 1 (0·2%) 0 1 (0·5%) 
Anterior Lumbar Surgery 1 (0·2%) 1 (0·5%) 0 
Anterior Thoracic Surgery 1 (0·2%) 1 (0·5%) 0 
Coccygectomy 1 (0·2%) 1 (0·5%) 0 
Costoplasty 1 (0·2%) 0 1 (0·5%) 
Posterior Cervical Instrumented Fusion 9 (2·2%) 4 (2·0%) 5 (2·5%) 
Posterior Cervical Metal Work Revision 2 (0·5%) 1 (0·5%) 1 (0·5%) 
Posterior Cervical/Thoracic Metal Work Removal 1 (0·2%) 1 (0·5%) 0 
Posterior Lumbar Bilateral Discectomy 1 (0·2%) 1 (0·5%) 0 
Posterior Lumbar Bilateral/Central Decompression 36 (8·8%) 14 (6·9%) 22 (10·8%) 
Posterior Lumbar Discectomy 259 (63·6%) 136 (66·7%) 123 (60·6%) 
Posterior Lumbar Instrumented Fusion 50 (12·3%) 23 (11·3%) 27 (13·3%) 
Posterior Lumbar Metal Work and Decompression 
Revision 
1 (0·2%) 0 
1 (0·5%) 
Posterior Lumbar Metal Work Removal 4 (1·0%) 2 (1·0%) 2 (1·0%) 
Posterior Lumbar Metal Work Revision 5 (1·2%) 1 (0·5%) 4 (2·0%) 
Posterior Lumbar Open Biopsy 1 (0·2%) 1 (0·5%) 0 
Posterior Lumbar Unilateral Decompression 1 (0·2%) 0 1 (0·5%) 
Posterior Thoracic Instrumented Fusion 4 (1·0%) 3 (1·5%) 1 (0·5%) 
Posterior Thoracic/Lumbar Instrumented Fusion 5 (1·2%) 3 (1·5%) 2 (1·0%) 
Data are n (%) 
 
 
 
 
 
 
  
  
 
Table S3. Prophylactic antibiotics administered intravenously 
 Total 
PVI + PVI Group 
(n=204) 
PVI + CHG Group 
(n=203) 
Cefuroxime 288 (70·8) 148(72·5) 140(69·0) 
Erythromycin 3 (0·7) 0 3(1·5) 
Flucloxacillin 16 (3·9) 8(3·9) 8(3·9) 
Flucloxacillin/Gentamicin 17 (4·2) 10(4·9) 7(3·4) 
Flucloxacillin/Gentamicin/Teicoplanin 1 (0·2) 0 1(0·5) 
None 1 (0·2) 1(0·5) 0 
Teicoplanin 22 (5·4) 8(3·9) 14(6·9) 
Teicoplanin/Cefuroxime 1 (0·2) 1(0·5) 0 
Teicoplanin/Gentamicin 58 (14·3) 28(13·7) 30(14·8) 
Data are n (%) 
 
  
 
 
 
  
Table S4. Total viable bacterial counts for aerobic and anaerobic growth from pre-skin disinfection skin swabs and post-skin disinfection surgical samples. 
 Aerobic Culture positive Anaerobic Culture positive 
 
 Mean 
2
TVC 
PVI + PVI Group 
 
Mean TVC 
PVI + CHG Group 
 
3
P 
value 
Mean TVC 
PVI + PVI Group 
 
Mean TVC 
PVI + CHG Group 
P 
value 
1
Skin swab  (Log10 CFU cm
-2
) 2·72 (0·23 - 5·00, 72)  2·60 (0·23 - 5·00, 49) 0·607 3·69 (0·23 - 5·00, 81) 3·55 (0·70 - 5·00, 58) 0·497 
1
Skin sample (Log10CFU g
-1
) 3·19 (1·56 - 4·75, 31) 3·15 (1·69 - 4·39, 11) 0·919 3·97 (1·56 - 5·29, 67) 3·80 (1·56 - 5·15, 44) 0·354 
1
Muscle Sample (Log10CFU g
-1
) 2·36 (1·57 - 3·35,   9) 2·20 (1·57 - 3·42,  6) 0·670 2·59 (1·27 - 4·41, 43) 2·67 (1·59 - 3·91, 20) 0·695 
1
Wound wash (Log10CFU 10ml
-1
) 2·27 (1·15 - 3·46, 19) 2·15 (1·38 - 3·43, 10) 0·684 2·27 (1·05 - 3·56, 46) 2·46 (1·18 - 3·60, 29) 0·332 
Data are mean (range, n). TVC= total viable counts. CFU=colony forming unit 
1
Zero values excluded. 
2
 Total viable counts from blood agar plates. 
3  
2-tailed t-test for equality of means 
Table S5. Bacteria isolated other than Staphylococcaceae, Propionibacteriaceae and 
Micrococcaceae 
Bacteria isolated from the 
skin of single patients 
Dermacoccus nishinomiyaensis, Janibacter sanguinis, Paracoccus yeei, 
Enterococcus faecalis, Klebsiella oxytoca, Moraxella osloensis, Ralstonia 
insidiosa 
Bacteria isolated from each 
of two patients 
Acinetobacter lwoffii, Rothia mucilaginosa 
 
 
